Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the NHS Centre for Reviews and Dissemination and Centre for Health Economics:

  • Yang H, Epstein D, Bojke L, Craig D et al. (August 2010). Golimumab for the treatment of psoriatic arthritis. York: NHS Centre for Reviews and Dissemination and Centre for Health Economics, University of York.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Centocor/Schering-Plough

II) Professional/specialist and patient/carer groups:

  • Psoriasis and Psoriatic Arthritis Alliance

  • Psoriasis Association

  • British Association of Dermatologists

  • British Health Professionals in Rheumatology

  • British Society for Rheumatology

  • Primary Care Rheumatology Society

  • Royal College

  • Royal of Pathologists

  • Royal of Physicians

III) Other consultees:

  • Department of Health

  • NHS Haringey

  • NHS Havering

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Abbott (adalimumab)

  • Pfizer (methotrexate, sulfasalazine)

  • Sanofi-Aventis (leflunomide)

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Centre for Reviews & Dissemination and Centre for Health Economics – York

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Eleanor Korendowych, Consultant Rheumatologist, nominated by British Society for Rheumatology – clinical specialist

  • Alex Anstey, Consultant Dermatologist, nominated by British Association of Dermatologists – clinical specialist

  • Philip Helliwell, nominated by British Society of Rheumatology – clinical specialist

  • Jana James, nominated by Psoriasis and Psoriatic Arthritis Alliance – patient expert

D. The following individual was nominated as NHS Commissioning expert by the selected NHS trust allocated to this appraisal. She gave her NHS commissioning personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. She was also invited to comment on the ACD.

  • Sue Ashwell, Chief Pharmacist, NHS Cambridgeshire selected by NHS Havering – NHS Commissioning expert

E. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy:

  • Merck Sharp & Dohme (formerly Schering-Plough)

  • National Institute for Health and Care Excellence (NICE)